Ax-003/Arimidex (Anastrozole) in the Adjuvant Therapy of Early Breast Cancer
Launched by ASTRAZENECA · Mar 18, 2008
Trial Information
Current as of May 10, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Postmenopausal women with early hormone receptor positive breast cancer/no metastasis
- Exclusion Criteria:
- • None
About Astrazeneca
AstraZeneca is a global biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative medicines across various therapeutic areas, including oncology, cardiovascular, respiratory, and autoimmune diseases. With a strong commitment to scientific research and patient-centric solutions, AstraZeneca leverages cutting-edge technology and a robust pipeline to address unmet medical needs. The company collaborates with healthcare professionals, academic institutions, and other organizations to advance clinical trials and deliver transformative therapies, aiming to improve health outcomes and enhance the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
H Brasch
Study Director
AstraZeneca Germany
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials